Sigyn Therapeutics, Inc. (OTCQB: SIGY) announced that a recent scientific discovery reported in Scientific American and published in Science Translational Medicine supports the potential use of its CardioDialysis™ technology to treat neuroinflammatory diseases. Researchers at Trinity College Dublin have provided the first clinical evidence of blood-brain barrier disruption and associated inflammation in living individuals suspected of having Chronic Traumatic Encephalopathy (CTE), a condition previously diagnosed only through post-mortem autopsy in former NFL players.
On March 21, Scientific American published an article titled “Brain’s Protective Barrier Stays Leaky for Years after Playing Contact Sports,” coinciding with the study in Science Translational Medicine. The study found that the blood-brain barrier may remain compromised and permeable for decades after an athlete’s retirement from sports involving repetitive head trauma. When the barrier is compromised, inflammatory molecules and pathogenic toxins in the bloodstream can enter the brain, triggering neuroinflammation that leads to abnormal tau protein accumulation, a hallmark of CTE. Researchers observed that former athletes appeared to be in a persistent state of chronic hyperinflammation.
The Trinity study adds to evidence that systemic inflammation is a key driver of neuroinflammation in disorders such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Sigyn Therapeutics is developing CardioDialysis, a next-generation blood purification technology that enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream. According to the company, CardioDialysis is uniquely positioned as a potential adjunct therapy for neuroinflammatory conditions due to its broad-spectrum mechanism.
Sigyn Therapeutics is pursuing a strategic transaction focused on using CardioDialysis to reduce systemic inflammation associated with traumatic brain injury (TBI). The company’s lead clinical indication for CardioDialysis remains cardiovascular disease, the leading cause of death worldwide. “It is becoming increasingly clear that CardioDialysis may play a meaningful role to slow the progression of neuroinflammatory disorders, particularly in high-risk individuals or during the early stages of disease,” stated Sigyn Therapeutics CEO Jim Joyce. “The dual reduction of inflammatory and pathogenic factors from the bloodstream could help stabilize the blood-brain barrier, which would limit the leakage of harmful molecules into the brain.”
CardioDialysis is the first therapy to integrate plasma separation and therapeutic adsorption within a single device. In cardiovascular disease, it aims to reduce inflammatory mediators fueling disease progression while lowering cholesterol-transporting lipoproteins that contribute to heart attacks and strokes. The technology is also being explored for sepsis, life-threatening viral infections, and neurological disorders associated with systemic inflammation. The company’s pipeline includes ImmunePrep™ for immunotherapeutic antibody delivery, ChemoPrep™ for targeted chemotherapy, and ChemoPure™ to reduce chemotherapy toxicity.
